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Background: Enteral tube feeding (ETF) has been evaluated in paediatric andmixed child and adult populations with cystic ﬁbrosis, demonstrating positive
outcomes from 6 months to 2 years post insertion. No studies have examined the longer term nutritional and clinical outcomes in an exclusively adult
population with cystic ﬁbrosis or compared the outcomes for those who meet standard criteria and opt to undertake or decline ETF.
Methods: Twenty three out of 380 patients attending the Leeds Regional Adult CF unit fulﬁlled the standard criteria for commencing ETF (CF
Trust, 2002) between 2004 and 2008. Weight, BMI, FEV1, FVC, CFRD, and number of intravenous antibiotic treatment days were collected at
1 year pre baseline, at baseline, and at 1, 2, and 3 years post baseline for all these patients whether they accepted or declined ETF.
Results: Seventeen of the 23 patients agreed to accept a programme of ETF, two of whom died within the ﬁrst year of ETF. In the remaining patients
(n = 15), weight increased by 19.5% from baseline (p b 0.001), BMI increased to within the normal range and lung function stabilised. There was no
reduction in the requirement for intravenous antibiotic treatment. The six patients who declined ETF had a decline in lung function and no weight gain.
Conclusion: Supplemental enteral tube feeding improves clinical outcomes when administered over 3 years, resulting in signiﬁcant weight gain, a
normal BMI and stabilisation of lung function. It does not reduce intravenous antibiotic treatment days. In contrast those patients eligible for, but
who declined ETF, showed a deterioration in lung function and a failure to gain weight and to achieve normal BMI status.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Adult; Enteral tube feeding; Outcome1. Introduction
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http://dx.doi.org/10.1016/j.jcf.2013.05.003Recognition of its importance has resulted in inclusion of
specialist dietitians in the multidisciplinary care team and
continuing improvements in nutritional status. National registry
data show a median body mass index of 21.8 kg/m2 [3] and
22.0 kg/m2 [4] for adult patients.
Despite these advances in nutritional support 21–25% of
adults remain underweight, women more than men [5,6]. The
interdependence of nutritional status and lung function is
apparent in both the UK CF Trust Annual data report (2010) [3]
and the CF Foundation Patient Registry (2011) [4]. Patients with a
BMI b19 kg/m2, had lower lung function (FEV1 25–60%)
compared to those with a BMI N19 kg/m2 (FEV1 60–90%).
However, 40% of adult respondents in a national survey reported
problems in gaining or maintaining their weight [7]. Improvementby Elsevier B.V. All rights reserved.
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therefore an important objective.
Specific standards for the escalation of nutritional intervention
guide nutritional support strategies. These recommendations advise
that ETF should be considered when dietary manipulation and oral
supplements have failed [8,9] and when BMI is b19 kg/m2, or
when there has been acute weight loss of 5% over a 2 month
period [9]. ETF may be required in end stage disease to enable
patients to achieve adequate nutritional status, an important
criterion for acceptance onto lung transplantation programmes.
Whilst a number of studies have demonstrated the nutritional
advantages of supplemental enteral tube feeding, these have been
conducted in either paediatric populations [10–13] or mixed child
and adult populations [14,15], with follow-up limited to up to
2.5 years after tube insertion. There are no studies that examine
nutritional and clinical outcomes in exclusively adult populations,
nor are there any studies that examine the longer term clinical
impact for those patients eligible for ETF who accept or decline
treatment.
The aims of this study were two-fold: firstly to examine our
adherence to the guidelines for initiation of ETF, and secondly to




Electronic case records for 380 patients attending the Adult
Cystic Fibrosis unit, Leeds UK, were retrospectively examined to
identify all patients who fulfilled the criteria for commencement
of ETF (CF Trust, 2002) between January 2004 and May 2008.
All patients had pancreatic insufficiency and were treated with
pancreatic enzyme replacement therapy.
The standard criteria used to identify participants were the
presence of a BMI b19 kg/m2, and/or 5% acute weight loss over
a 2 month period with a failure of oral nutritional supplements to
adequately improve nutritional status (CF Trust, 2002).
2.2. Measures
Age, gender, genetic mutation, presence of meconium ileus,
presence of gastro-oesophageal reflux, respiratory pathogen
status, the mode and reason for commencing ETF, and the time
taken to accept ETF once standard criteria had been met were
recorded for each participant. Anthropometric and respiratory
parameters including weight (kg), height (m), BMI (kg/m2),
forced expiratory volume in 1 second (FEV1 % predicted) and
forced vital capacity (FVC % predicted) were noted at one year
time intervals from 1 year prior to starting ETF, at baseline, and
at one year intervals for up to 3 years. The number of days of
intravenous antibiotic treatment in the year before starting ETF
and in each succeeding year of the study was documented.
Weight change was calculated by comparing weight at each
time point to baseline weight and then calculating the percentage
weight change achieved. Similarly this was undertaken for change
in lung function.Participants were classified into 3 categories according to
weight change from baseline to 3 years. These were weight loss
(any loss), weight maintenance (zero change) and weight gain
(categorised into those gaining b1 kg/m2, 1–3 kg/m2 and
N3 kg/m2). The category of weight gain was documented at
each of the time intervals from year 1 to year 3. Data were also
recorded to demonstrate the proportion of patients achieving a
BMI of 20 kg/m2.
The presence of cystic fibrosis related diabetes (CFRD),
complications of ETF, and mortality were documented annually.
We also examined the relationship between baseline lung
function and % weight change at 1 and 3 years, applying a
cut-off of 45% FEV1 (% predicted) at 3 years, to examine
whether longer term nutritional gain is achieved at lower levels of
lung function. The cut-off value of 45% FEV1 (% predicted) was
chosen according to the mean value reported in previous studies
in CF, above and belowwhich there is an association with clinical
outcome in ETF [11,22]. Mortality data were analysed to
compare any differences in presentation of patients who died
with those who survived.
In those patients who declined ETF the same measures were
recorded at the point where the standard criteria for starting
ETF were met and at annual intervals for 3 years.
All patients consumed a polymeric 2 kcal/ml enteral tube
feed, providing 20–60% of daily energy intake as an overnight
enteral tube feed, allowing free dietary intake during the day.
2.3. Exclusion criteria
Exclusion criteria were classified as the presence of pancreatic
sufficiency, pregnancy or lung transplantation during the 3 year
follow-up period.
2.4. Ethical approval
Ethical approval was stated as not required by Leeds East
Medical Ethics committee (2009) for this retrospective case note
review.
2.5. Statistical analysis
Data were analysed for normal distribution. Descriptive
statistics were used to evaluate the demographical characteristics
for all patients opting to undertake or decline enteral tube feeding.
Unpaired t-tests (2 tailed) were used to compare anthropometric
data and lung function between those who opted to undertake or
decline ETF. Pearson's Chi2 test was used to compare proportions
between the two groups.
Any mortality data were then excluded from the analysis and
analysed separately. In participants surviving to 3 years, longitu-
dinal effects of enteral tube feeding upon weight gain, BMI,
pulmonary function (FEV1 and FVC) and days of intravenous
antibiotic treatment in each treatment group were evaluated using
ANOVA (repeat measures) to explore the differences over time
between the two groups over the 3 year time period and paired
t-tests (1 tailed) for comparison between successive years. The
percentage of patients achieving standard norms for nutritional
Table 1
Patient characteristics at baseline (start or decline of enteral tube feeding).
Physical characteristics Enteral tube feeding Mean difference (ETF v non-ETF) 95% CI p Value
Accepted Declined
Number 17 (74%) 6 (26%)
Age 21.8 (±3.6) 23.0 (±5.7) 1.2 (−3.4 to 5.7) p = 0.6
Gender 8 Males (47%) 3 Males (50%) p = 1.0
Genotype
DF508/DF508 8 5 p = 0.1
DF508/Unknown 6 – p = 0.1
DF508/3659delC 1 – p = 0.1
DF508/2184delA 1 – p = 0.1
DF508/621+1 (GNT) 1 1 p = 0.1
Respiratory colonisation
Pseudomonas aeruginosa 15 (88.2%) 5 (83.3%) p = 0.6
Non-Pseudomonas aeruginosa 1 (5.9%) 0 p = 0.8
Burkholderia cepacia 1 (5.9%) 1 (16.7%) p = 0.5
Meconium ileus at birth 4 (23.5%) 1 (17%) p = 0.6
Gastro-oesophageal reflux 5 (29.4%) 1 (17%) p = 0.5
Presence of cystic fibrosis related diabetes 5 (29.4%) 0 p = 0.2
Presentation
BMI b19 kg/m2 12 (70.6%) 6 (100%) p = 0.5
Acute weight loss and BMI b19 kg/m2 5 (29.4%) 0 p = 0.2
Oral supplement use 12/17 (70.5%) 6 (100%) p = 0.2
Weight (kg) 46.4 (±5.5) 8.9 (±3.9) 2.7 (−7.6 to 2.6) p = 0.3
BMI (kg/m2) 16.8 (±1.6) 18.05 (±1.7) 1.3 (−2.1 to 0.2) p = 0.08
FEV1 (%) 39.5 (±18.9) 56.3 (±21.0) 16.8 (−36.0 to 2.4) p = 0.08
FVC (%) 54.8 (±20.4) 83.0 (±18.5) 28.2 (−60.0 to −10.8) p = 0.007
Unpaired t-tests used to compare continuous data; Pearson's Χ2 test used to compare proportions.
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correlation was used to examine whether any association was
present between baseline lung function and % weight gain at
1 year and 3 years in both groups. Data were analysed using SPSS
version 19.0 (Chicago, Illinois) and results were classed as
statistically significant when p b 0.05.
3. Results
Twenty-three patients (11 male, 12 female) fulfilled the criteria
for ETF between January 2004 and May 2008. Seventeen patients
(74%) accepted ETF. Demographic data are recorded in Table 1.
Of those patients who opted to undertake ETF, 5 presented with
BMI b19 kg/m2 and acute weight loss and 12 patients with BMI
b19 kg/m2 alone. Eleven (65%) had PEG insertion, 5 (29%) had
nasogastric feeding and 1 (6%) had a jejunostomy. All those who
declined ETF presented solely with BMI b19 kg/m2. In this initial
sample (n = 17), differences were observed between those who
accepted or declined ETF at baseline for FEV1 [39.5% (ETF) v
56.3% (non-ETF) p = 0.11], and FVC [54.8% (ETF) v 83%
(non-ETF), p = 0.007] although the former was not significant.
Two patients died within the study, and subsequent analysis was
undertaken on those who accepted ETF and survived (n = 15) and
those who declined (n = 6).
3.1. Nutritional status
The median time taken from first discussion of ETF to
insertion of a nasogastric tube or PEG was 5 months (range
0.2–36 months). Those who accepted ETF and survived the3 year period (n = 15) lost weight in the year preceding
baseline with a mean reduction of 49.6 kg down to 45.9 kg and
a resultant 7.5% loss of body weight (p = 0.002). On starting
ETF they went on to demonstrate significant weight gain over
3 years [F(1.7,24.5) = 12.6, p b 0.001], equating to a mean %
increase in weight when compared to baseline (Yr 0), of 16.0%
(1 year), 18.3% (2 years), 19.6% (3 years) and actual weight
gains of 7.3 kg, 8.4 kg and 9.0 kg at equivalent time periods.
This was sufficient to increase mean BMI from 16.5 kg/m2 to
19.8 kg/m2 and to within the normal reference range for BMI
of 19–25 kg/m2 over the 3 year period (Table 2). Of these
surviving patients, 100% had gained weight at 1 year and
2 years after starting ETF and 13 (87%) had gained weight at
3 years, with 8 (53%) of patients who accepted ETF gaining
N3 BMI units (kg/m2) and achieving a BMI of N20 kg/m2.
Significant differences in weight were observed over the
3 years between those who had ETF compared to those who
declined treatment [F(1.9,36.6) = 4.8, p = 0.015] [Fig. 1]. The
latter group showed no percentage increase in weight from
baseline −0.5% (1 year), −1.4% (2 years), 0.2% (3 years)
[F(3,15) = 0.32, p = 0.8] and their BMI remained unchanged at
18.9 kg/m2 throughout (Table 2). Of these 6 participants, 2
(33.3%) gained weight, 1 (17.7%) maintained weight and 3
(50%) lost weight throughout the 3 year period, with none
achieving a BMI of 20 kg/m2.
3.2. Lung function
In the ETF group, a significant decline was observed in FEV1
(52.9% to 41.1%, p b 0.001) in the year prior to starting ETF,
Table 2
Mortality data and changes in clinical parameters for patients surviving 3 year time period.
Clinical parameters 1 year pre Year 0 (baseline) Year 1 Year 2 Year 3
Categories of weight change [number (%)] from Yr 0 (baseline)
• Weight loss ETF – – 0 (0%) 0 (0%) 2 (13.3%)
Non-ETF – – 2 (33.3%) 4 (66.6%) 3 (50%)
• Weight maintenance ETF – – 0 (0%) 0 (0%) 0 (0%)
Non-ETF – – 1 (16.7%) 0 (0%) 1 (16.7%)
• Weight gain ETF – – 15 (100%) 15 (100%) 13 (86.7%)
Non-ETF – – 3 (50%) 2 (33.3%) 2 (33.3%)
Categories of weight gain
• b1 kg/m2 ETF – – 1 (6.6%) 6 (40%) 1 (6.7%)
Non-ETF – – 3 (50%) 2 (33.3%) 0 (0%)
• 1–3 kg/m2 ETF – – 7 (46.7%) 2 (13.3%) 4 (26.7%)
Non-ETF – – 0 (0%) 0 (0%) 2 (33.3%)
• N3 kg/m2 ETF – – 7 (46.7%) 7 (46.7%) 8 (53.3%)
Non-ETF – – 0 (0%) 0 (0%) 0 (0%)
Achieved BMI 20 kg/m2
(number, cumulative %)
ETF 0 (0%) 0 (0%) 3 (20%) 7 (46.7%) 8 (53%)
Non-ETF 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Weight (kg) ETF 49.6 (±4.4) 45.9 (±4.8) p = 0.002 53.2 (±5.0) p = 0.000 54.2 (±8.3) p = 0.21 54.8 (±8.6) p = 0.14
Non-ETF 48.8 (±4.2) 49.0 (±3.6) p = 0.39 48.7 (±3.1) p = 0.37 48.2 (±2.5) p = 0.23 48.9 (±2.2) p = 0.18
BMI [kg/m2] ETF 18.1 (±1.4) 16.5 (±1.4) p = 0.002 19.2 (±1.6) p = 0.000 19.4 (±2.2) p = 0.30 19.8 (±2.4) p = 0.15
Non-ETF 17.8 (±0.7) 18.1 (±0.6) p = 0.28 17.9 (±0.6) p = 0.34 17.8 (±0.5) p = 0.24 18.9 (±0.4) p = 0.22
FEV1 (%) ETF 52.9 (±16.5) 41.1 (±17.7) p = 0.000 46.4 (±19.3) p = 0.01 45.3 (±19.8) p = 0.32 42.3 (±18.3) p = 0.09
Non-ETF 59.6 (±25.1) 56.3 (±19.2) p = 0.17 51.0 (±17.3) p = 0.13 48.3 (±21.6) p = 0.18 45.3 (±19.9) p = 0.17
FVC (%) ETF 73.3 (±13.6) 58.4 (±18.2) p = 0.004 65.9 (±19.7) p = 0.01 68.7 (±21.2) p = 0.48 60.4 (±18.2) p = 0.10
Non-ETF 85.5 (±18.8) 83.0 (±15.1) p = 0.32 78.8 (±18.8) p = 0.12 77.7 (±19.4) p = 0.41 72.0 (±16.6) p = 0.13
IV treatment (days) ETF 27.7 (±31.8) 36.9 (±38.6) p = 0.11 57.6 (±43.2) p = 0.001 64.9 (±74.2) p = 0.29 80.1 (±95.1) p = 0.06
Non-ETF 14.0 (±25.6) 20.0 (±24.3) p = 0.16 22.8 (±30.4) p = 0.13 12.0 (±16.5) p = 0.18 27.0 (±36.0) p = 0.17
Prevalence of CFRD
(number, cumulative %)
ETF 4 (26.7%) 4 (26.7%) 4 (26.7%) 6 (40%) 8 (53%)
Non-ETF 1 (16.7%) 1 (16.7%) 1 (16.7%) 1 (16.7%) 1 (16.7%)
Complications (number,
cumulative %)
ETF – 0 (0%) 0 (0%) 1 (6.7%) 1 (6.7%)
Non-ETF – 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Mortality a (number,
cumulative %)
ETF – 2 (11.8%) 2 (11.8%) 2 (11.8%) 2 (11.8%)
Non-ETF – 0 (0%) 0 (0%) 0 (0%) 0 (0%)
p Values indicate changes from previous year's value (paired t-test, 1 tailed).
a Mortality data excluded from continuous data analysis.
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those who declined ETF (Table 2). FEV1 (%) increased from
41.1% to 46.4% during the first year, a significant increase from
baseline of 12.9% (p = 0.01). Over the 3 year period FEV1
remained above baseline levels, increasing from 41.1% (baseline)
to 42.3% (3 years) [F(2,31.2) = 0.52, p = 0.6]. In those who
opted not to tube feed, FEV1 decreased from 56.3% at baseline to
45.3% at 3 years [Fig. 2], a decrease of 19.5% from baseline
values over the 3 year time period [F(3,15) = 2.7, p = 0.08].
Overall, baseline FEV1 was not related to weight gain either at
1 year (r = −0.1, p = 0.73) or at 3 years (r = 0.31, p = 0.26). In
those with FEV1 b45% at baseline who accepted ETF, 10/11
(91%) gained weight at 3 years, compared to only 3/5 (60%) of
those who declined ETF [Fig. 3].
3.3. Intravenous (IV) antibiotic treatment
Despite stabilisation of lung function, there was a rising
trend in the requirement for intravenous antibiotic treatment
during the 3 year period in patients receiving ETF, increasing
from 28 days in the year prior to commencing ETF to 80 days
in the third year [F(1.2,14.2) = 2.0, p = 0.18]. Although this
was not significant overall, a significant rise in iv treatmentwithin the first year of ETF was observed, with treatment days
increasing from 36.9 to 56.7 days (p = 0.01) in those choosing
ETF. This pattern was not observed in patients who declined tube
feeding, who despite their decline in lung function had fewer days
of intravenous antibiotic treatment throughout the course of
3 years [F(1.8,9.1) = 1.5, p = 0.26]. There was also no signif-
icant difference between those who accepted or declined ETF
[F(1.2,21.2) = 1.2, p = 0.41] over the 3 year period.
3.4. Comorbidities and mortality
Five of 17 (29%) patients receiving ETF had pre-existing
CFRD compared to none who opted not to feed. A further 4
(23.5%) developed CFRD over the next 3 years of the study
(Table 2). Only 1 (16.7%) of those patients who declined ETF
developed CFRD.
Two (11.7%) patients died at baseline after starting ETF,
compared with none in the group that declined ETF. These patients
had an FEV1 of 11% and 28% respectively at the start of ETF and
had lost 46% and 61% of lung function in the preceding year. In
contrast to those who survived and accepted ETF, they had greater
loss of lung function in the year preceding ETF [−53.5%
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Fig. 1. Mean % weight change from baseline and mean actual weight for those


































































Fig. 2. Mean % change in lung function from baseline and mean actual change






















Baseline lung function (FEV1) at Yr 0
ETF
non-ETF
Fig. 3. Association of baseline lung function with % weight gain at 3 years.
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(survivors ETF), p = 0.3], although not significant. Cause of death
for these patients was recorded as acute bowel obstruction
(regarded as inoperable due to poor lung function status) and
viral illness respectively, each unrelated to enteral tube feeding.
No major complications were observed. One patient (6%)
had minor local infection.
4. Discussion
This is the first study to report the longer term nutritional and
clinical outcomes associated with ETF in an exclusively adult
population. Once standard criteria were met, 74% of patients
accepted nocturnal ETF. There was a median delay of 5 months
for patients to make the decision to proceed once ETF had been
discussed with them. Five patients (29% of those accepting ETF)
took 18–36 months to make this decision, highlighting the
difficulties experienced by patients in considering and accepting
the need for enteral feeding support. The reasons for delay are
unknown but may be due to a number of factors and are complex
in nature. In young adolescents classified as underweight it has
been shown that a significant percentage attempted to avoid
weight gain [16] and similarly adult women have been noted to
engage in behaviours that challenge their nutritional treatment,
impacting on quality of life and survival [17].
A further 26% of all patients who met the initial standard
criteria for entry to the study declined the procedure. They had
greater lung function at baseline, less intravenous antibiotic
treatment and a lower prevalence of CFRD, which suggests that
the presence of co-morbidities and the stage of disease progression
may play a significant role in the decision making process.
Gunnell et al. (2005) [18] explored the views of paediatric patientstowards a number of factors affecting tube placement and
concluded that there were significant differences in attitudes and
beliefs towards PEG insertion between those who opted to
undertake or decline the procedure, including its perceived impact
on sport, activity, pain experienced at placement and poor
perceptions from others, highlighting the importance of peer
approval. Patients' reasons for non-placement were not sought
within our own study, but would provide valuable information on
621H. White et al. / Journal of Cystic Fibrosis 12 (2013) 616–622the role of different educational, motivational or peer input into
patient decision making.
For those who opted to undertake ETF, the nutritional
advantages were evident early in treatment. They gained 16%
of their initial body weight during the first year and 19% by
3 years. This rapid early weight gain is consistent with other
studies that have reported weight gains of 11–20% at 1 year in
mixed child and adult populations [14,19]. As in this study,
weight gain has been reported as greatest in the first year of
supplemental feeding [12,13]. A mean weight gain of 7 kg was
also achieved within the first 12 months of ETF in a sub-group of
12 adult patients [20] in a population with similar baseline
nutritional status to the current study, suggesting that improve-
ments in nutritional status are similar and replicable within adult
centres.
Lung function in CF is inextricably linked with nutritional
status. Significant early gains in lung function within the first year
of enteral tube feeding, followed by stabilisation of lung function
were observed in the present study indicating pulmonary benefits
for patients of whom 65% had an FEV1 b40% at baseline. Other
studies report maintenance rather than improvements in lung
function following ETF [10,12,13,20,21]. Although one report
has shown that greater nutritional gain is achieved when lung
function is higher (60%) at baseline [22], our own study indicates
that nutritional benefits were consistently achieved at lower
baseline lung function values: 90% of those presenting with
FEV1 b45% gaining weight throughout the 3 year period.
Evidence of weight gain at these levels of baseline lung function
suggests that patients presenting with a range of disease severity
can benefit from the introduction of ETF.
ETF was associated with stabilisation of lung function but the
nutritional and respiratory benefits of ETF did not result in a
reduction in intravenous antibiotic therapy requirements. More-
over, patients who declined ETF did not experience a significant
increase in intravenous antibiotic treatment. The increasing
number of treatment days required in those accepting ETF and
the divergence between groups over the 3 year time period was
not explained by respiratory pathogen growth, which was similar
between groups nor by the presence of gastro-oesophageal reflux
(GOR). GOR has been proposed as impacting on lung function
over time [23], but was not markedly different between groups
within this study.
The lower intravenous antibiotic requirements of those who
declined ETF may be explained by their higher baseline lung
function (56% compared to 41% in the ETF group) and a
possible underlying characteristic of the group to resist invasive
therapies, as opposed to oral calorie supplements alone. The
former also suggests that low body weight alone is insufficient
to persuade patients to undertake ETF. It is possible that
patients declined ETF over the study period because they did
not feel that their condition was significantly deteriorating. Had
their frequency of intravenous antibiotics increased they may
have opted for more aggressive intervention. It is also possible
that the greater decline in nutritional status and lung function in
the year prior to baseline for patients accepting ETF had a
subsequent impact on future treatment requirements. Mean
losses in lung function of 22% in those who chose ETF weretherefore retrievable but at an apparent higher treatment cost
over the longer term. The observational nature of the study
prevents firm conclusions as to whether it was nutritional
intervention or antibiotic treatment that prevented decline in
lung function.
Almost one third of patients who had ETF had co-existing
cystic fibrosis related diabetes (CFRD) at the start of treatment
indicating the more advanced stage of disease in this group. The
prevalence of CFRD increased to 53% during the 3 year period
of tube feeding which supports the need for close monitoring of
blood glucose once ETF is initiated. The incidence of cystic
fibrosis related diabetes has been frequently noted as a
complication of ETF [12,24,25], although a causal relationship
has not been established. It is possible that ETF may
inadvertently affect the pathophysiology of CFRD by altering
the deposition of adipose tissue. Fat has been shown to be
unevenly distributed in patients with CF who have undergone
gastrostomy, with greater fat mass in the abdomen compared to
controls [26]. In the general population deposition of fat in the
viscera and central abdomen is strongly associated with Type 2
diabetes, in contrast to subcutaneous deposition which may act as
a buffer for excess dietary energy.
Other complications were minimal. In agreement with other
studies PEG and nasogastric feeding appear safe and acceptable
to patients [12,13,15]. Two patients receiving ETF died, a
mortality rate of 11.7%, both deaths occurring within the first
year of ETF and in patients with lung function b30%. In contrast
three of four other patients with baseline lung function values of
30% or less, gained lung function over the 3 year period. Oliver
et al. (2004) [11] reported the mortality rates in a cohort of 37
children and adolescents with CF who had gastrostomy tube
feeding and concluded that there was a significantly higher risk of
mortality when FEV1 was b50%. Baseline lung function did not
explain clinical outcome for those undertaking ETF in the current
study, although it is of note that those who died had more
significant respiratory decline in the year prior to ETF, losing
approximately 50% of their lung function (FEV1). Mortality rates
were small within the current study and insufficient to base firm
conclusions on, but it suggests that the speed of respiratory
decline prior to ETF may be an important factor in determining
outcome rather than baseline FEV1 itself.
A limitation of this study is its relatively small sample size, but
it is the only study examining ETF in a solely adult population and
does so over the longest reported follow-up period to date. Further
limitations lie in the study design itself, where self-selection of
ETF allows the potential to bias study findings through
differences in baseline lung function and disease severity. Small
study numbers also have the potential to reduce the significance of
findings where strong trendsmay still be evident. Lastly, the study
relies on weight and BMI alone as markers of nutritional status.
Additional measures were considered but have inherent difficul-
ties associatedwith their interpretation. Albumin is acknowledged
as an insensitive marker, subject to reduction when infection
markers such as C-reactive protein are raised. Vitamin A status
can be similarly affected by infection status and is also subject to
adherence, whilst Vitamin D is affected by sunlight exposure.
Future studies would however benefit from measures which
622 H. White et al. / Journal of Cystic Fibrosis 12 (2013) 616–622specify the type of change achieved in body composition,
including anthropometric measures such as triceps skinfold
thickness, mid arm muscle circumference or other measurements
that can differentiate changes in body composition such as dual
x-ray absorptiometry (DXA). In addition the future inclusion of
accurate data regarding ETF intake, dietary intake and adherence
would aid in determining the relationship between nutritional
intake and body composition measures.
In conclusion, ETF is associated with significant weight gain,
sufficient to achieve a BMI within the normal range and with
stabilisation of lung function over the longer term. These benefits
are not seen in patients who decline intervention. While their
weight remained stable, lung function declined by 19.5% from
baseline during the 3 years of the study. Despite improvements in
both nutritional status and lung function, there was an increase in
the frequency of intravenous antibiotic treatment over the study
period in the ETF group. Nutritional gain was achieved in
patients with baseline FEV1 as low as 20%, suggesting that
nutritional benefit can occur late in the disease process.
Consideration should therefore be given as to how to best inform
patients of these benefits in order to allow an informed choice.
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